SPRUCE BIOSCIENCES, INC. 8-K

What Happened
Spruce Biosciences, Inc. (SPRB) filed an 8-K on March 9, 2026 announcing three material items: it entered a new Open Market Sale AgreementSM (an “at‑the‑market” or ATM program) with Jefferies LLC to sell shares from time to time; it issued a press release reporting full-year financial results for the year ended December 31, 2025 (the press release is furnished as Exhibit 99.1); and it appointed Corwin Dale Hooks as Chief Commercial Officer effective March 9, 2026. The new Sales Agreement replaces the prior agreement dated February 25, 2022.

Key Details

• Sales Agreement with Jefferies LLC dated March 9, 2026 allows Spruce to sell common stock from time to time under its Form S-3 registration (File No. 333-291152).
• Jefferies may sell shares as agent or principal, including negotiated block trades or sales on Nasdaq; company will pay commissions up to 3.0% of gross proceeds.
• Company is not obligated to sell any shares; prior ATM with Jefferies was terminated as of March 9, 2026.
• Corwin Dale Hooks named CCO effective March 9, 2026; base salary $480,000, annual bonus opportunity up to 40% of base, and a 11,000‑share restricted stock unit (RSU) inducement award vesting over four years.
• FY2025 financial results and corporate updates were released on March 9, 2026 (see Exhibit 99.1 for full text).

Why It Matters

• The ATM (Sales Agreement) gives Spruce flexibility to raise capital quickly under its S-3 shelf, which can help fund operations or commercialization efforts; any share sales would dilute existing shareholders and incur up to a 3% sales commission.
• Replacing the prior ATM centralizes future equity placement with Jefferies under updated terms; the company is not required to sell shares, so timing and amount of any dilution remain at management’s discretion.
• Hiring an experienced commercial executive (Corwin Hooks) signals a focus on commercial strategy and potential product launches; his compensation (salary, bonus, RSU) will affect operating expense and long‑term equity dilution.
• Investors should review the March 9, 2026 press release (Exhibit 99.1) for the company’s FY2025 results and read the Sales Agreement and compensation documents (Exhibits 1.1, 10.1, 10.2) for full terms.